HC Wainwright Has Lowered Expectations for LAVA Therapeutics (NASDAQ:LVTX) Stock Price

LAVA Therapeutics (NASDAQ:LVTX) had its price target decreased by investment analysts at HC Wainwright from $6.00 to $2.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 94.17% from the stock’s previous close.

Several other research analysts have also weighed in on the stock. JMP Securities restated a “market perform” rating and set a $6.00 target price on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 price objective (down from $11.00) on shares of LAVA Therapeutics in a research note on Thursday, December 12th. Citizens Jmp downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Finally, Leerink Partnrs cut LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $3.33.

LAVA Therapeutics Stock Up 4.2 %

NASDAQ:LVTX opened at $1.03 on Friday. The firm’s fifty day simple moving average is $1.62 and its 200-day simple moving average is $1.78. The stock has a market cap of $26.11 million, a PE ratio of -1.00 and a beta of 0.43. LAVA Therapeutics has a fifty-two week low of $0.96 and a fifty-two week high of $6.47.

Institutional Investors Weigh In On LAVA Therapeutics

A number of large investors have recently bought and sold shares of LVTX. XTX Topco Ltd acquired a new position in shares of LAVA Therapeutics in the second quarter worth $55,000. Virtu Financial LLC purchased a new stake in LAVA Therapeutics during the 3rd quarter worth about $32,000. Finally, Pathway Financial Advisors LLC increased its position in LAVA Therapeutics by 70.8% during the 3rd quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock worth $170,000 after purchasing an additional 42,500 shares in the last quarter.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.